Current position

Ray Dalio’s Guardant Health Inc (GH) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2020Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares162.48KHighest verified quarter-end share count
Quarters reported24Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Guardant Health Inc in Q3 2020. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 4.24K shares. The latest verified filing showed: Sold 68.2% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 68.2% of the position−9.11K shares · 4.24K shares remained
Filing context

Quarter-end price $150.03 · Estimated holding basis $94.25

Q1 2026
Sold 52.8% of the position−14.94K shares · 13.35K shares remained
Filing context

Quarter-end price $92.37 · Estimated holding basis $94.25

Q4 2025
Bought 605.5% more+24.28K shares · 28.29K shares reported after the change
Filing context

Quarter-end price $102.14 · Estimated holding basis $94.25

Q3 2025
Bought 3.6% more+140 shares · 4.01K shares reported after the change
Filing context

Quarter-end price $62.48 · Estimated holding basis $46.44

Q2 2025
Sold 23.7% of the position−1.20K shares · 3.87K shares remained
Filing context

Quarter-end price $52.04 · Estimated holding basis $45.86

Q1 2025
Sold 59.6% of the position−7.47K shares · 5.07K shares remained
Filing context

Quarter-end price $42.60 · Estimated holding basis $45.86

Portfolio importance

How important is Guardant Health Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#893of 997 reported positions
Peak portfolio weight0.1%Q1 2021
Best historical rank#156Q4 2020
At peak importanceQ1 2021
GH
0.1%
Largest holding
11.0%
Cross-investor discovery

Who else owns Guardant Health Inc?

Also reported by 2 other tracked investors in their latest verified filings.

Cathie WoodARK Investment Management
GH0.5% of reported portfolio
Joel GreenblattGotham Asset Management
GH0.0% of reported portfolio
Explore Guardant Health Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$174.902026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$150.03Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$94.25Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.